Detalhe da pesquisa
1.
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.
Bioconjug Chem
; 35(2): 140-146, 2024 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265691
2.
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Blood
; 134(21): 1832-1846, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31511238
3.
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Blood
; 129(11): e26-e37, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28122742
4.
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.
Blood
; 128(6): 839-51, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27288519
5.
N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
Bioorg Med Chem Lett
; 28(12): 2153-2158, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29759726
6.
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Blood
; 121(7): 1188-99, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23264594
7.
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Acta Haematol
; 132(1): 75-86, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504330
8.
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
Drug Resist Updat
; 16(3-5): 68-72, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24169539
9.
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Nat Commun
; 15(1): 275, 2024 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177131
10.
The nuclear receptor DHR3 modulates dS6 kinase-dependent growth in Drosophila.
PLoS Genet
; 6(5): e1000937, 2010 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-20463884
11.
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.
ACS Med Chem Lett
; 14(7): 949-954, 2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37465299
12.
A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
Oncogene
; 41(39): 4459-4473, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008466
13.
Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice.
Cancer Res
; 82(6): 1098-1109, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131871
14.
Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
BMC Cancer
; 11: 24, 2011 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21247487
15.
Rheb is an essential regulator of S6K in controlling cell growth in Drosophila.
Nat Cell Biol
; 5(6): 559-65, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12766775
16.
dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1.
Nat Cell Biol
; 4(3): 251-5, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11862217
17.
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
Bioorg Med Chem Lett
; 20(8): 2609-13, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20231096
18.
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
Bioorg Med Chem Lett
; 20(5): 1724-7, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20138510
19.
Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.
Sci Rep
; 10(1): 20044, 2020 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33208877
20.
A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays.
Leuk Lymphoma
; 61(13): 3052-3065, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32799592